TScan Therapeutics Reports Q1 2026 Results with Improved Net Loss
TScan Therapeutics reported its first-quarter 2026 financial results, showing an improved net loss of $28.7 million compared to $34.1 million in the prior-year quarter due to reduced expenses and interest income. Revenue declined to $1.0 million from $2.2 million primarily because of lower research activity with Amgen.
Topics: biotechnology clinical-stage_company financial_performance